Navigation Links
Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott

WHIPPANY, N.J., Jan. 6, /PRNewswire/ -- Halo Pharmaceutical, Inc., a privately held specialty pharmaceutical company, has announced today the completion of its acquisition of the Whippany-NJ Manufacturing and Research facility from Abbott (NYSE: ABT). At over 200,000 square feet, Halo's facilities encompasses highly-diverse manufacturing and warehousing capabilities, including an impressive array of formulation services, operations for the aseptic filling of topical ointments, solid dosage forms (tablets and capsules), liquids, suppositories, associated packaging (tablet, powder, liquids and HUD) and ample laboratory space for formulation development, pre-clinical and clinical supplies and support of commercial operations. An additional asset is the site's capability to manufacture controlled substances (C2-C5) and an API manufacturing unit with an outstanding track-record of meeting DEA requirements. "We are extremely excited about the acquisition of this outstanding facility," said Douglas Kollmorgen, President of Halo Pharmaceutical. "The facility and the people who are continuing on with Halo, have a long and proud history here. Under the management of Abbott, the Whippany facility has been an exemplary production operation. We welcome the opportunity to continue that tradition of excellence for our customers going forward."

Halo's initial complement of personnel will consist of close to 80 highly-experienced pharmaceutical industry veterans from Abbott, and is expected to grow rapidly as the business develops further. "We are combining the best elements of traditional pharma with the innovation, agility and strong work ethic of a startup company," said Mohd Asif, Chief Financial Officer and head of the transaction team. "One of our great differentiators will be our focus on infusing the operation with our own unique culture, while preserving the focus on product quality, customer service and regulatory compliance." On the subject of the facility's heritage, Mr. Asif also explained that "it is essential that we recognize the significant contribution that has been made by Abbott in helping to smooth the transition of the Whippany facility to Halo stewardship, and to continue the strong legacy of this plant and its people."

A cornerstone of Halo's plan for success in a competitive environment will be a considerable focus on product quality, customer service and regulatory compliance. "This is a rare opportunity to build off the successes of a great company like Abbott," said John C. (Jack) Garvey, Vice President, Quality. "The compliance record of the Whippany site has been exemplary, and the culture is clearly focused on compliance. These important foundational elements will enable the creation of a systems approach to quality, with a focus on science-based, product-driven control frameworks that meet or exceed current FDA regulatory requirements and expectations."

Halo is currently seeking and evaluating opportunities for contract manufacturing, in-licensing, contract laboratory services, and the acquisition of branded products from companies looking to rationalize their product portfolios.

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service, specialty pharmaceutical company, offering state-of-the-art contract manufacturing, early stage formulation development and laboratory services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic filling, granulation, blending, tableting, coating, packaging and related warehousing operations. Halo Pharmaceutical is a privately-held company.

SOURCE Halo Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CEVA Logistics Awarded Best 3PL Provider for Pharmaceutical, Chemical, HazMat and Fresh Food Supply Chains
2. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
3. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
4. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
5. China Sky One Medical, Inc. Closes Acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.
6. China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
7. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
8. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
9. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
10. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid ... America. As people age, more care is needed, especially with Alzheimer’s, dementia and ... professionals are being overworked. The forgotten part of this equation: 80 percent of ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any ... opener. Utilize presets featuring self-animating drop zones, lines, bars, and text with the ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... Karnataka (PRWEB) , ... November 27, 2015 , ... ... world, Health-E-minds, an innovative online platform for mental health and wellness consultation, has ... , This partnership will bridge the knowledge gap experienced by parents and bring ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
Breaking Medicine Technology: